Business
Class Action Lawsuit Filed Against Capricor Therapeutics, Inc. (CAPR) - Recover Losses - Contact Levi & Korsinsky Before September 15, 2025
New York, New York--(Newsfile Corp. - September 3, 2025) - If you suffered a loss on your Capric...
About this update from Caprock Mining Corp
[{"type":"text","content":"Class Action Lawsuit Filed Against Capricor Therapeutics, Inc. (CAPR) - Recover Losses - Contact Levi & Korsinsky Before September 15, 2025New York, New York--(Newsfile Corp. - September 3, 2025) - If you suffered a loss on your Capricor Therapeutics, Inc. (NASDAQ: CAPR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/capricor-therapeutics-inc-lawsuit-submission-form-2?prid=165130&wire=5&utm_campaign=9or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Cannot view this video? Visit:https://www.youtube.com/watch?v=WkeFApDBai4THE LAWSUIT: A class action securities lawsuit was filed against Capricor Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025.CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application.Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025.WHAT'S NEXT? If you suffered a loss in Capricor stock during the relevant time frame - even if you still hold your shares - go to ht...